// App-Quantinova.ai

TPS478 : A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2).

Researchers

Presenter

  • Andrew X. Zhu

Principal Investigators

  • Peter R. Galle

  • Masatoshi Kudo

  • Richard S. Finn

  • Ling Yang

  • Paolo Abada

  • Shao-Chun Chang

  • Josep M. Llovet

Medical Centers

  • Massachusetts General Hospital Cancer Center, Boston, MA

  • First Department of Internal Medicine, University Medical Center Mainz, Mainz, Germany

  • Department of Gastroenterology and Hepatology, Kinki University School of Medicine, Osaka-Sayama, Japan

  • Ronald Reagan UCLA Medical Center, Los Angeles, CA

  • Eli Lilly and Company, Bridgewater, NJ

  • Eli Lilly, Indianapolis, IN

  • Eli Lilly and Company, Indianapolis, IN

  • Liver Cancer Program, Division of Liver Diseases, Mount Sinai School of Medicine, New York, NY

Locations

  • United States

  • Germany

  • Japan

Companies

  • Eli Lilly and Compan

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

  • Oncology (ONC)

Disease

  • Liver cancer

  • Encephalopathy

  • Solid malignancies

Biomarkers

  • Alpha-fetoprotein

  • Solute Carrier Family 12 Member 2

Drug/Treatment

  • Alfa-fetoprotein

  • Ramucirumab

  • Sorafenib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • NCT02435433

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved